Research ArticleArticle
Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody–positive Cases
Hidenaga Kawasumi, Yasuhiro Katsumata, Akira Nishino, Shinya Hirahara, Yasushi Kawaguchi, Masataka Kuwana and Hisashi Yamanaka
The Journal of Rheumatology April 2018, jrheum.170997; DOI: https://doi.org/10.3899/jrheum.170997
Hidenaga Kawasumi
From the Institute of Rheumatology, Tokyo Women’s Medical University; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. Supported in part by the Japanese Ministry of Education, Culture, Sports, Science, and Technology Grants-in-Aid for Scientific Research (KAKENHI Grant Number 17K16215). This study was also supported in part by the Nagao Takeshi Nanbyo Foundation. The funders of the study had no role in the study design, conduct of the study, data collection, or data interpretation or preparation of the report. MK holds a patent on an anti-MDA5 antibody measuring kit. H. Kawasumi, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Katsumata, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; N. Nishino, MD, Institute of Rheumatology, Tokyo Women’s Medical University; S. Hirahara, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Kawaguchi, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; H. Yamanaka, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University. Address correspondence to Dr. Y. Katsumata, Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan. E-mail: katsumata@twmu.ac.jp. Accepted for publication January 19, 2018.
Yasuhiro Katsumata
From the Institute of Rheumatology, Tokyo Women’s Medical University; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. Supported in part by the Japanese Ministry of Education, Culture, Sports, Science, and Technology Grants-in-Aid for Scientific Research (KAKENHI Grant Number 17K16215). This study was also supported in part by the Nagao Takeshi Nanbyo Foundation. The funders of the study had no role in the study design, conduct of the study, data collection, or data interpretation or preparation of the report. MK holds a patent on an anti-MDA5 antibody measuring kit. H. Kawasumi, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Katsumata, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; N. Nishino, MD, Institute of Rheumatology, Tokyo Women’s Medical University; S. Hirahara, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Kawaguchi, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; H. Yamanaka, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University. Address correspondence to Dr. Y. Katsumata, Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan. E-mail: katsumata@twmu.ac.jp. Accepted for publication January 19, 2018.
Akira Nishino
From the Institute of Rheumatology, Tokyo Women’s Medical University; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. Supported in part by the Japanese Ministry of Education, Culture, Sports, Science, and Technology Grants-in-Aid for Scientific Research (KAKENHI Grant Number 17K16215). This study was also supported in part by the Nagao Takeshi Nanbyo Foundation. The funders of the study had no role in the study design, conduct of the study, data collection, or data interpretation or preparation of the report. MK holds a patent on an anti-MDA5 antibody measuring kit. H. Kawasumi, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Katsumata, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; N. Nishino, MD, Institute of Rheumatology, Tokyo Women’s Medical University; S. Hirahara, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Kawaguchi, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; H. Yamanaka, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University. Address correspondence to Dr. Y. Katsumata, Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan. E-mail: katsumata@twmu.ac.jp. Accepted for publication January 19, 2018.
Shinya Hirahara
From the Institute of Rheumatology, Tokyo Women’s Medical University; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. Supported in part by the Japanese Ministry of Education, Culture, Sports, Science, and Technology Grants-in-Aid for Scientific Research (KAKENHI Grant Number 17K16215). This study was also supported in part by the Nagao Takeshi Nanbyo Foundation. The funders of the study had no role in the study design, conduct of the study, data collection, or data interpretation or preparation of the report. MK holds a patent on an anti-MDA5 antibody measuring kit. H. Kawasumi, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Katsumata, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; N. Nishino, MD, Institute of Rheumatology, Tokyo Women’s Medical University; S. Hirahara, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Kawaguchi, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; H. Yamanaka, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University. Address correspondence to Dr. Y. Katsumata, Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan. E-mail: katsumata@twmu.ac.jp. Accepted for publication January 19, 2018.
Yasushi Kawaguchi
From the Institute of Rheumatology, Tokyo Women’s Medical University; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. Supported in part by the Japanese Ministry of Education, Culture, Sports, Science, and Technology Grants-in-Aid for Scientific Research (KAKENHI Grant Number 17K16215). This study was also supported in part by the Nagao Takeshi Nanbyo Foundation. The funders of the study had no role in the study design, conduct of the study, data collection, or data interpretation or preparation of the report. MK holds a patent on an anti-MDA5 antibody measuring kit. H. Kawasumi, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Katsumata, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; N. Nishino, MD, Institute of Rheumatology, Tokyo Women’s Medical University; S. Hirahara, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Kawaguchi, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; H. Yamanaka, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University. Address correspondence to Dr. Y. Katsumata, Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan. E-mail: katsumata@twmu.ac.jp. Accepted for publication January 19, 2018.
Masataka Kuwana
From the Institute of Rheumatology, Tokyo Women’s Medical University; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. Supported in part by the Japanese Ministry of Education, Culture, Sports, Science, and Technology Grants-in-Aid for Scientific Research (KAKENHI Grant Number 17K16215). This study was also supported in part by the Nagao Takeshi Nanbyo Foundation. The funders of the study had no role in the study design, conduct of the study, data collection, or data interpretation or preparation of the report. MK holds a patent on an anti-MDA5 antibody measuring kit. H. Kawasumi, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Katsumata, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; N. Nishino, MD, Institute of Rheumatology, Tokyo Women’s Medical University; S. Hirahara, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Kawaguchi, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; H. Yamanaka, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University. Address correspondence to Dr. Y. Katsumata, Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan. E-mail: katsumata@twmu.ac.jp. Accepted for publication January 19, 2018.
Hisashi Yamanaka
From the Institute of Rheumatology, Tokyo Women’s Medical University; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. Supported in part by the Japanese Ministry of Education, Culture, Sports, Science, and Technology Grants-in-Aid for Scientific Research (KAKENHI Grant Number 17K16215). This study was also supported in part by the Nagao Takeshi Nanbyo Foundation. The funders of the study had no role in the study design, conduct of the study, data collection, or data interpretation or preparation of the report. MK holds a patent on an anti-MDA5 antibody measuring kit. H. Kawasumi, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Katsumata, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; N. Nishino, MD, Institute of Rheumatology, Tokyo Women’s Medical University; S. Hirahara, MD, Institute of Rheumatology, Tokyo Women’s Medical University; Y. Kawaguchi, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; H. Yamanaka, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University. Address correspondence to Dr. Y. Katsumata, Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan. E-mail: katsumata@twmu.ac.jp. Accepted for publication January 19, 2018.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody–positive Cases
Hidenaga Kawasumi, Yasuhiro Katsumata, Akira Nishino, Shinya Hirahara, Yasushi Kawaguchi, Masataka Kuwana, Hisashi Yamanaka
The Journal of Rheumatology Apr 2018, jrheum.170997; DOI: 10.3899/jrheum.170997
Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody–positive Cases
Hidenaga Kawasumi, Yasuhiro Katsumata, Akira Nishino, Shinya Hirahara, Yasushi Kawaguchi, Masataka Kuwana, Hisashi Yamanaka
The Journal of Rheumatology Apr 2018, jrheum.170997; DOI: 10.3899/jrheum.170997